Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357115 | 1.00 | HDAC4 (0.42) | HDAC4HDAC1HDAC6EPHX1CTSS | |
| SCHEMBL13605051 | 1.00 | HDAC4 (0.42) | HDAC4HDAC1HDAC6EPHX1CTSS | |
| SCHEMBL24298159 | 0.83 | EPHX1 (0.46) | HDAC4HDAC1HDAC6EPHX1CTSS | |
| SCHEMBL90706 | 0.83 | EPHX1 (0.46) | HDAC4HDAC1HDAC6EPHX1CTSS | |
| SCHEMBL89503 | 0.83 | EPHX1 (0.46) | HDAC4HDAC1HDAC6EPHX1CTSS | |
| SCHEMBL3122669 | 0.83 | HDAC4 (0.39) | HDAC4HDAC1HDAC6EPHX1CTSS | |
| SCHEMBL90608 | 0.81 | EPHX1 (0.44) | HDAC4HDAC1HDAC6EPHX1CTSS | |
| SCHEMBL90287 | 0.81 | EPHX1 (0.44) | HDAC4HDAC1HDAC6EPHX1CTSS | |
| SCHEMBL1414447 | 0.80 | EPHX1 (0.48) | HDAC4HDAC1HDAC6EPHX1CTSS | |
| SCHEMBL12733104 | 0.80 | EPHX1 (0.48) | HDAC4HDAC1HDAC6EPHX1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC (US) | 2014-05-08 | — | — | US | disclosed |
| US-8642554-B2 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2070928-A1 | 7-azaindol-3-ylacrylamides active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070928-A1 | 7-azaindol-3-ylacrylamides active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-06-17 | — | — | EP | disclosed |
| US-20090104151-A1 | SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS | JOYANT PHARMACEUTICALS, INC (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104151-A1 | SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS | BID, BAD, BIRC3 | HDAC4 930/4885HDAC1 1084/4885HDAC6 1207/4885 |
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | BID, BAD, BIRC3 | HDAC4 930/4885HDAC1 1084/4885HDAC6 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.